Ambrosini P J
J Clin Psychopharmacol. 1984 Oct;4(5):247-53.
The qualitative aspects of drugs used in enuresis control or associated with enuresis or urinary incontinence and the pathological disorders associated with enuresis or urinary incontinence are reviewed. The literature to date does not clarify the factors that account for tricyclic antidepressant effectiveness in enuresis. However, it does reveal that enuresis and urinary incontinence are common symptoms of basal ganglion disorders. Furthermore, pharmacological agents that depress or block dopamine activity produce urinary incontinence or enuresis, while those drugs augmenting the noradrenergic system facilitate continence. It is postulated that urinary incontinence and enuresis are secondary to an imbalance of catecholamine neurotransmitters within basal ganglion structures. A hypothesis is proposed suggesting that dopamine agonists could be viable therapeutic alternatives to tricyclics in treating enuresis and urinary incontinence. Additional clinical drug trials are needed to assess the characteristic responses of specific catecholamine agents in urinary incontinence and enuresis.
本文综述了用于控制遗尿症或与遗尿症或尿失禁相关的药物的定性方面，以及与遗尿症或尿失禁相关的病理障碍。迄今为止的文献并未阐明三环类抗抑郁药在遗尿症中有效的因素。然而，它确实表明遗尿症和尿失禁是基底神经节疾病的常见症状。此外，抑制或阻断多巴胺活性的药物会导致尿失禁或遗尿症，而增强去甲肾上腺素能系统的药物则有助于控制排尿。据推测，尿失禁和遗尿症是基底神经节结构内儿茶酚胺神经递质失衡的继发结果。提出了一个假说，表明多巴胺激动剂在治疗遗尿症和尿失禁方面可能是三环类药物可行的治疗替代方案。需要进行更多的临床药物试验来评估特定儿茶酚胺药物在尿失禁和遗尿症中的特征性反应。
